search
Back to results

INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Intervention 1
Intervention 2
Sponsored by
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Type 2 Diabetes Mellitus focused on measuring Type 2 diabetes mellitus, glycemic control

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Diagnosis of Type 2 DM according to criteria of the World Health Organisation of one or more years of disease duration.
  • Age from 30 to 80 years.
  • HbA1C ≥ 9% (DCCT) according to the last blood test carried out during the 12 months prior to inclusion in the study
  • No changes in the treatment that can influence the main variable during the 3 months prior inclusion in the study.
  • Accepting to participate in the study and signing of the informed consent form.

Exclusion criteria:

  • Patient refuses to participate and any other condition that prevents signing the informed consent form.
  • Other types of diabetes: Type 1 DM, gestational diabetes and diabetes secondary to other diseases.
  • Pharmacological treatments that interfere with carbohydrate metabolism, such as steroids.
  • Life expectancy under 2 years.
  • Current treatment for cancer other than basocellular or epidermoid skin cancer.
  • Severe mental disease and dementia.
  • Heart failure Class III or IV (NYHA).
  • Renal transplant or current treatment with dialysis.
  • Alcohol and drug abuse.
  • Pregnancy or intention to get pregnant.
  • Breastfeeding.
  • Chronic treatment with steroids; treatment with steroids during the 2 months prior inclusion in the study.
  • Pharmacological treatment for weight loss during the 2 months prior to inclusion in the - study.
  • Treatment with immunosuppressants.
  • Haemoglobinopathies and chronic anaemia.
  • Body Mass Index > 45 mg/kg2 (1)
  • Participation in clinical trials for medicines.
  • Patients with conditions that prevent follow up and completion of protocol.

Sites / Locations

  • Laura Montero

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

Intervention 1

Intervention 2

Control group

Arm Description

Diabetes specific consultation + multicomponent intervention aimed at professionals and patients

Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.

No intervention. Data of the control groups will be retrieved from the SIDIAP.

Outcomes

Primary Outcome Measures

Glycaemic control measured by HbA1c

Secondary Outcome Measures

lipid profile control as measured by the mean concentration of LDL-cholesterol, non-HDL cholesterol and triglycerides
measurement of systolic blood pressure and of diastolic blood pressure
control of chronic complications associated with type 2 diabetes according to the protocol of the CIH
direct health costs of type 2 diabetic patients
evaluation of patient satisfaction using spanish version of diabetes treatment satisfaction questionnaire (DTSQ)
control of risk factors, smoking and exercise: Patient Activation Measure questionnaire
evaluation of therapeutic inertia: specific questionnaire created by Redgedaps
evaluation of quality of life using spanish version of diabetes quality of life questionnaire (EsDQOL)

Full Information

First Posted
December 4, 2015
Last Updated
February 12, 2019
Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Collaborators
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT02663245
Brief Title
INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control
Official Title
INTEGRA Study: Intervention in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control on Primary Health Care.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
December 2015 (Actual)
Primary Completion Date
October 31, 2018 (Actual)
Study Completion Date
December 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Collaborators
Sanofi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The intensification of the management for the control of glycaemia and other risk factors in patients with type 2 diabetes (DM2) results in a reduction of diabetes-related complications. The strategy to increase the competences of primary care professionals to improve health care has been mainly prompted by the current context of limited resources and restricted access to specialty care. This study aims to evaluate the effectiveness and cost-effectiveness of an integral intervention carried out by primary care professionals with the following components: detection of patients with poor diabetic control; introduction of a specific consultation on diabetes followed by virtual and telephone specialist support; introduction of other measures to overcome patients and professionals barriers to treatment. The main objective of the study is to determine if glycaemic control as measured by the mean concentration of HbA1c of poorly controlled patients improves when these patients are evaluated and treated in primary care under the integral strategy proposed in this study. The INTEGRA project also includes Phase 1 (qualitative research study), which is aimed at identifying viable strategies to suppress barriers to treatment; these strategies have been included to the intervention study (phase 2). Phase 2 is a controlled, quasi-experimental intervention that involves 9 primary care centres of 3 regions (Lleida, Girona, Barcelona). The participants are patients with DM2 with poor glycaemic control that meet all the inclusion criteria and sign the informed consent. The intervention study will have three arms: (1) Control Group; (2) Intervention Group 1 (diabetes specific consultation + additional measures originated in phase 1; and (3) Intervention Group 2 (additional measures originated in phase 1). Phase 1 has been conducted during the last 6 months previous to the initiation of the proposed intervention study and consisted of a qualitative design (individualized interviews with randomly selected patients in each of the participating centers); this qualitative study has contributed to design the final intervention applied on phase 2, particularly, implementing additional measures as coaching sessions to health professionals of the participating centers and automated messaging to patients with reminder and motivational objectives. Phase 2 consists of a recruitment period of 6 months, followed by a 12-month follow-up for each patient

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 diabetes mellitus, glycemic control

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
564 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention 1
Arm Type
Experimental
Arm Description
Diabetes specific consultation + multicomponent intervention aimed at professionals and patients
Arm Title
Intervention 2
Arm Type
Experimental
Arm Description
Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
No intervention. Data of the control groups will be retrieved from the SIDIAP.
Intervention Type
Other
Intervention Name(s)
Intervention 1
Intervention Description
Diabetes specific consultation Basic training in clinical guidelines Platform of communication for professionals Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0. 7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach. Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes.
Intervention Type
Other
Intervention Name(s)
Intervention 2
Intervention Description
7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach. Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0. Basic training in clinical guidelines. Platform of communication for professionals. Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes.
Primary Outcome Measure Information:
Title
Glycaemic control measured by HbA1c
Time Frame
12 months
Secondary Outcome Measure Information:
Title
lipid profile control as measured by the mean concentration of LDL-cholesterol, non-HDL cholesterol and triglycerides
Time Frame
12 months
Title
measurement of systolic blood pressure and of diastolic blood pressure
Time Frame
12 months
Title
control of chronic complications associated with type 2 diabetes according to the protocol of the CIH
Time Frame
12 months
Title
direct health costs of type 2 diabetic patients
Time Frame
12 months
Title
evaluation of patient satisfaction using spanish version of diabetes treatment satisfaction questionnaire (DTSQ)
Time Frame
12 months
Title
control of risk factors, smoking and exercise: Patient Activation Measure questionnaire
Time Frame
12 months
Title
evaluation of therapeutic inertia: specific questionnaire created by Redgedaps
Time Frame
12 months
Title
evaluation of quality of life using spanish version of diabetes quality of life questionnaire (EsDQOL)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Diagnosis of Type 2 DM according to criteria of the World Health Organisation of one or more years of disease duration. Age from 30 to 80 years. HbA1C ≥ 9% (DCCT) according to the last blood test carried out during the 12 months prior to inclusion in the study No changes in the treatment that can influence the main variable during the 3 months prior inclusion in the study. Accepting to participate in the study and signing of the informed consent form. Exclusion criteria: Patient refuses to participate and any other condition that prevents signing the informed consent form. Other types of diabetes: Type 1 DM, gestational diabetes and diabetes secondary to other diseases. Pharmacological treatments that interfere with carbohydrate metabolism, such as steroids. Life expectancy under 2 years. Current treatment for cancer other than basocellular or epidermoid skin cancer. Severe mental disease and dementia. Heart failure Class III or IV (NYHA). Renal transplant or current treatment with dialysis. Alcohol and drug abuse. Pregnancy or intention to get pregnant. Breastfeeding. Chronic treatment with steroids; treatment with steroids during the 2 months prior inclusion in the study. Pharmacological treatment for weight loss during the 2 months prior to inclusion in the - study. Treatment with immunosuppressants. Haemoglobinopathies and chronic anaemia. Body Mass Index > 45 mg/kg2 (1) Participation in clinical trials for medicines. Patients with conditions that prevent follow up and completion of protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Àngels Molló, MD
Organizational Affiliation
Institut Català de la Salut
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dídac Mauricio, MD, PhD
Organizational Affiliation
Germans Trias i Pujol Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laura Montero
City
Tàrrega
State/Province
LLeida
ZIP/Postal Code
25300
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
30732583
Citation
Mollo A, Berenguera A, Rubinat E, Vlacho B, Mata M, Franch J, Bolibar B, Mauricio D. INTEGRA study protocol: primary care intervention in type 2 diabetes patients with poor glycaemic control. BMC Fam Pract. 2019 Feb 7;20(1):25. doi: 10.1186/s12875-019-0916-9.
Results Reference
derived

Learn more about this trial

INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control

We'll reach out to this number within 24 hrs